Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins

表达 TRPV 阳离子通道蛋白的稳定细胞系的工程改造

• 批准号: 521672-2017
• 负责人: Weaver, Ian
• 金额: $ 1.81万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639334
• 关键词: Engineering; Stable; Cell; Lines; Expressing

Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developingbiopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the NorthernShort-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeuticactivity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain celltypes (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver otherdrugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by thecurrent lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under thisEngage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties ofthe C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target andenter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company'sproduct line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targetingspecific cell types. Broadening and solidifying the company's pipeline with such products will lead topartnerships with larger biopharma companies and expand Soricimed's drug marketability.

Soricimed Bioburma，Inc.是一家位于新玩法的萨克维尔/蒙克顿的公司，开发基于soricidin的生物制药化合物，soricidin是一种在北方短尾鼩的唾液中发现的麻痹蛋白。该公司的主要化合物SOR-C13是一种合成的13聚体肽，其治疗活性基于其与钙通道TRPV 6的相互作用，TRPV 6在某些细胞类型（例如癌细胞）中的表达升高。此外，SOR-C13（C肽）的衍生物可用作载体，将其他药物直接递送到携带TRPV 6的细胞中。这种药物输送平台的优化受到目前缺乏重要的内部工具的阻碍;过度表达TRPV 6通道的稳定细胞系。在这项参与资助下，Weaver博士的实验室将开发这种细胞系，使Soricimed能够确定C肽衍生物的哪些特性可以改善它们与TRPV通道的相互作用，从而提高它们靶向和进入携带这些通道的细胞的能力。这些知识反过来又会导致公司的产品线扩大，新的和改进的治疗C肽，和新的C肽/药物缀合物靶向特定的细胞类型。扩大和巩固公司的管道与这些产品将导致与更大的生物制药公司的合作伙伴关系，并扩大Soricimed的药物市场。